NCT00141284已完成4 期
A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 12
- 试验地点
- 6
- 主要终点
- To Evaluate the safety of nelfinavir 1,250 mg orally taken twice daily in HIV/HCV co infected adult subjects with compensated cirrhosis (Child Pugh A) or hepatic fibrosis.
研究概览
简要总结
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV/ Hepatitic C co infected with documented HCV viremia evidence for cirrhosis and or hepatic fibrosis on liver biopsy, positive fibrosis index, stable health
排除标准
- •Decompensated cirrhosis (Child Pugh B or C)
- •Pregnant or lactating women
- •History of previous antiretrovirals > 14 days
结局指标
主要结局
To Evaluate the safety of nelfinavir 1,250 mg orally taken twice daily in HIV/HCV co infected adult subjects with compensated cirrhosis (Child Pugh A) or hepatic fibrosis.
次要结局
- To evaluate the pharmacokinetics of nelfinavir and M8, the major metabolite.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19COVID-19NCT05164133Hoffmann-La Roche2
终止
1 期
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationBronchiolitis Obliterans SyndromeNCT03978637Incyte Corporation23
已完成
1 期
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.Healthy VolunteersNCT02189733Ablynx, a Sanofi company24
招募中
1 期
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsAccelerated Phase Chronic Myeloid LeukemiaBlast Phase Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaLeukemiaAcute Myeloid LeukemiaLymphomaSolid TumorsNCT03934372Incyte Biosciences International Sàrl70
已完成
1 期
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of CebranopadolPharmacokineticNCT03882762Tris Pharma, Inc.34